What motivates us?
Current insulin therapy addresses two key factors in diabetes treatment: timing and dosage. But, these insulins fail to address another critically important factor: location, or where the insulin is working. In fact, insulin therapies fail to restore normal physiology in people with diabetes in part because they do not adequately deliver insulin where pancreatic insulin goes in the body of a person without diabetes: the liver.
Diasome is committed to developing Hepatocyte Directed Vesicle (HDV) technology, a new liver targeting additive for insulin. We are working to use HDV to restore normal insulin physiology in order to allow people with diabetes to return to more predictable and healthy blood sugar control. Diasome: #wetellinsulinwheretogo
Glucose control in the United States T1D community is not improving.
More than 79% of people living with type 1 diabetes do not achieve the American Diabetes Association recommended HbA1C target.1
Current insulin therapy is sub‑optimal.
This is because subcutaneous insulin administration generates pharmacokinetics and pharmacodynamics that do not replicate normal insulin release from the pancreas.
The impact on the lives of people living with T1D and those who care for them.
Up to 10% of people living with type 1 diabetes suffer from an episode of severe low blood sugar accompanied by seizure or coma, every 3 months.1
1 Beck and al, State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018, Diabetes Technology and Therapeutics, 2019
These stats are startling, but they’re only the tip of the iceberg.
Average HbA1C levels in people living with type 1 diabetes fall around 8%, with less than 21% achieving the recommended ADA HbA1C target. People living with type 1 diabetes of lower socioeconomic status demonstrate average HbA1C values ranging from 8-9%, while average HbA1C of adolescents aged 15-18 is around 9%. Additionally, minority populations – specifically Hispanic or black, non-Hispanic individuals – demonstrate average HbA1C values ranging from 8-9%.
Actually, average HbA1C in the type 1 diabetes population rose from 7.8% to 8.4% from 2012 to 2018 despite significant increase in the use of sophisticated medical devices technologies.
Why is this?
Recent innovations in the field have focused on technologies that enable people with diabetes to control how much insulin is required (dosage) and how quickly or slowly insulin acts within the body (timing). These technologies have failed to recognize a key element: the critical importance of where insulin acts in the body (location) and the crucial role that the liver plays in natural, physiologic blood sugar control.
To achieve optimal outcomes, insulin therapy needs to address all three key components of insulin therapy: dosage, timing, and location.